Title page

Baseline Characteristics and Outcomes of 180 Egyptian COVID-19 Patients Admitted to Quarantine Hospitals of Ain Shams University: A Retrospective Comparative Study

Running title: COVID-19 in Egypt

Sara I. Taha^{a*}, Sara F. Samaan^b, Aalaa K. Shata^c, Shereen A. Baioumy^d, Shaimaa A. Abdalgeleel^e, Mariam K. Youssef^a

^a Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

^b Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

^c Department of Pulmonary Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

^d Department of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Egypt. ^e Department of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt

Authors:

*Sara Ibrahim Taha, M.D., Ph.D.

Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

E-mail: <u>dr_sara_ib@med.asu.edu.eg</u> ORCID: <u>https://orcid.org/0000-0001-8224-8701</u>

Sara Farid Samaan, M.D., Ph.D.

Lecturer of Internal Medicine/ Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

E-mail: <u>Dr.sara_farid@yahoo.com</u>

Aalaa Kamal Shata, M.D., Ph.D.

Lecturer of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt. E-mail: aalaashata@yahoo.com

Shereen Atef Baioumy, M.D., Ph.D.

Lecturer of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Email: <u>drshereenatef@yahoo.com</u> ORCID: <u>https://orcid.org/0000-0002-2188-6790</u>

Shaimaa Abdalaleem Abdalgeleel, M.D., Ph.D.

Lecturer of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt. E-mail: shaimaa.abdalgeleel@nci.cu.edu.eg ORCID: https://orcid.org/0000-0003-0994-7703

Mariam Karam Youssef, M.D., Ph.D.

Lecturer of Clinical Pathology/Hematology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.

E-mail: <u>Dr.mariam_karam@hotmail.com</u> ORCID: <u>https://orcid.org/0000-0003-2075-3889</u>

* Corresponding Author:

Sara Ibrahim Taha, MD, PhD Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University. Address: Ain Shams University, Abassia, Cairo, Egypt Office tel., fax: + (202) 24346308 Mobile: + (20) 1125360009 E-mail: dr_sara_ib@med.asu.edu.eg

https://orcid.org/0000-0001-8224-8701

1 Abstract:

2 **Background:** COVID-19 mortality, severity, and recovery are major global concerns, but they 3 are still insufficiently understood, particularly in the Middle East. Methods: This retrospective 4 study comprised 180 adult Egyptian COVID-19 patients who were categorized and compared to evaluate if there was a link between their clinical and laboratory findings at hospital admission 5 6 and disease severity and mortality risk. Results: Of all patients enrolled, 27.8% had severe 7 disease and 13.9% died during their hospital stay. Diabetes mellitus (46.7%), hypertension (36.1%) and chronic obstructive pulmonary disease (COPD) (33.3%) were the most frequent 8 9 associated co-morbidities. Severe patients and non-survivors were significantly older compared 10 to their corresponding groups. Their absolute neutrophil count, procalcitonin (PCT), ESR, Creactive protein (CRP), AST, ALT, LDH, D-dimer, and ferritin levels were all significantly 11 12 higher (P \leq 0.05), whereas their absolute lymphocyte count was significantly lower (P \leq 0.05). COPD (OR: 3.294; 95% CI: 1.199-9.053; P= 0.021), diabetes mellitus (OR: 2.951; 95% 13 CI:1.070-8.137; P = 0.037), ferritin $\geq 350 \text{ ng/mL}$ (OR: 11.08; 95% CI: 2.796-41.551; P = 0.001), 14 15 AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991; P= 0.021), CT-SS ≥ 17 (OR: 1.205; 95% CI: 1.089-1.334; P \leq 0.001) and absolute lymphocyte count $< 1 \times 10^{3} / \mu L$ (OR: 4.002; 95% CI: 1.537-16 10.421; P= 0.005), were all linked to a higher risk of COVID-19 severity. Furthermore, COVID-17 19 in-hospital mortality was predicted by dyspnea (OR: 4.006; 95% CI: 1.045-15.359; P= 0.043), 18 $CT-SS \ge 17$ (OR: 1.271; 95% CI: 1.091-1.482; P= 0.002) and AST ≥ 40 IU/L (OR: 2.89; 95% 19 20 CI: 1.091-7.661; P= 0.033). Conclusions: Clinical and laboratory data of COVID-19 patients at 21 their hospital admission may aid in identifying early risk factors for severe illness and a high 22 mortality rate, as well as determining the most effective management for them.

23 **Keywords:** Coronavirus; COVID-19; Egypt; Indicators; Mortality; Severity.

25 INTRODUCTION:

Coronavirus disease 2019 (COVID-19) is a highly contagious infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that was first discovered in Wuhan, China, in early December 2019. Since then, the disease has rapidly spread to become a global epidemic [1]. The first COVID-19 case in Egypt was reported in February 2020, and since then, the number of cases has been dramatically rising. According to the Egyptian Ministry of Health and Population, there were more than 266,000 confirmed COVID-19 cases and almost 15,200 COVID-19 deaths throughout Egypt and its governorates as of June 5, 2021 [2].

33 COVID-19 infection is most commonly transmitted through respiratory droplets, as well as human-to-human contact [3]. It causes a wide range of symptoms that can lead to patient 34 mortality, making it difficult to treat and control [4]. It also depletes hospital resources, such as 35 ICU beds and mechanical ventilators, especially in low-resource countries [5]. So far, no specific 36 antiviral therapy for COVID-19 has been found to be effective, and clinical management is based 37 38 primarily on symptom control [6]. Several vaccinations began to emerge toward the end of 2020. According to the World Health Organization (WHO), there were 102 vaccines in clinical trials 39 and 184 vaccines in preclinical trials as of May 28, 2021 [7]. 40

The goal of this study was to understand more about COVID-19 baseline features and outcomes in Egyptian patients, which could aid in detecting early risk factors for poor prognosis and guiding proper patient management.

44 **METHODOLOGY:**

45 Study subjects and settings

This retrospective study included 180 COVID-19 adult patients (age \geq 18 years old) admitted from March 1 to April 30, 2021 to the Quarantine Hospitals of Ain-Shams University (Eldemerdash hospital and Field hospital), Cairo, Egypt. Only confirmed SARS-CoV-2 cases through nasopharyngeal swabs real-time reverse-transcriptase–polymerase-chain-reaction (RT– PCR) assays, in accordance with WHO guidance [8], were enrolled in the study. Pregnant women, patients with missing data and those who had hematological diseases or immunological disorders were excluded from the study.

53 Data collection:

Baseline data including: age, gender, presenting symptoms, comorbidities and chronic diseases, chest computed tomography (CT), ICU admission necessity, length of hospital stay and outcome (survival or non-survival), as well as baseline routine laboratory test results (CBC with differential counts, CRP, ESR, ferritin, D-dimer, PCT, LDH, AST and ALT) were acquired from medical records of all included patients.

59 Before the start, The Ain Shams University Faculty of Medicine Research Ethics Committee 60 (REC) gave its permission for the study to be carried out. Informed consent was waived due to 61 the retrospective nature of this study. Data were collected from hospital records in an anonymous 62 pattern, kept private and confidential. They were solely utilized for the purpose of research.

63 **Patient categorization:**

All included patients were categorized according to guidelines of the management protocol of COVID-19 patients released by Ain Shams University Hospitals [9]. Patients were considered to have severe/critical disease if one or more of the following were present: oxygen saturation \leq 93% at rest; dyspnea with a respiratory rate \geq 30 breath/min; arterial partial oxygen pressure

68 (PaO2)/fraction of inspired oxygen (FiO2) \leq 300 mmHg; respiratory failure with a need for 69 mechanical ventilation; ICU admission need with shock, or organ failure syndrome. COVID-19 70 patients who did not meet these criteria but had a positive COVID-19 nucleic acid test were 71 classified as having mild to moderate disease severity (non-severe).

72 Calculation of CT scoring system:

Each of the five lung lobes was visually assessed for the extent of involvement, whether unilateral or bilateral; peripheral, central, or both; upper lobe predominance, lower lobe predominance, or both; and then graded on a scale of 0 to 5 (degree of involvement: 0%, less than 5%, 5–25%, 26–49%, 50–75%, and > 75%, respectively). The sum of the individual lobar grades was then used to create a score that ranged from 0 to 25 [10,11].

78 Statistical methods:

The results were generated using the Statistical Package of Social Science (SPSS) (version 26). Quantitative numerical data were described as means and standard deviations (SD) or medians and ranges. While qualitative data were described as frequencies and percentages. Comparisons were done using the Mann-Whitney –U test or the Chi-square test or Fisher's exact test as appropriate. The significant variables in the univariate analysis were subjected to stepwise logistic regression, and the odds ratio (OR) and its 95% confidence intervals (CI) were calculated to estimate the risk. Probability (p-value) ≤ 0.05 was considered significant.

86 **RESULTS:**

87 Demographics and associated co-morbidities:

88 A total of 180 COVID-19 patients were enrolled in this study. Their median (IOR) age was 48 years (15-94). Thirty five percent of the patients were males and 65% were females. The most 89 common associated co-morbidities were diabetes mellitus (46.7%), hypertension (36.1%) and 90 91 chronic obstructive pulmonary disease (COPD) (33.3%). Of all the studied population, 27.8% (n=50) had severe disease and 13.9% (n=25) died during their hospital stay. Patients of these 2 92 subgroups were significantly older compared to non-severe patients (median: 60 years (IQR:22-93 91) vs. 43 years (15-94); P=0.004) and survivors (57.0 years (27-80) vs 45.0 years (15-94); 94 P=0.005), respectively. In terms of sex, differences between the studied subgroups were not 95 96 significant. Demographics and associated co-morbidities are shown in Table 1.

97 Baseline clinical characteristics and patients' outcomes:

Table 2 shows baseline clinical characteristics and outcomes of all studied patients and 98 according to COVID-19 severity and mortality. The most frequent symptoms at admission were 99 fatigue (90.6%), myalgia (75.0%), arthralgia (73.9%), fever (69.4%), dyspnea (69.4%) and 100 101 cough (68.9%). Only dyspnea was significantly associated with COVID-19 in-hospital mortality (88.0% vs. 66.5%; P= 0.030). Patients with severe COVID-19 had significantly higher rates of 102 103 thrombotic manifestations (38.0% vs. 22.3%; P=0.030), but no significant difference between 104 non-survivors and survivors was found (36.0% vs. 25.2%; P=0.255). Regarding CT-SS, significantly higher scores were observed in severe patients (median: 21 (IQR: 5-23) vs. 15 (0-105 24); P \leq 0.001) and non-survivors (20 (0-24) vs. 7 (0-23); P \leq 0.001) compared to their 106 corresponding groups. 107

In the 180 patients, the ICU admission rate was 30.6% with significant higher rates in severe patients and non-survivors compared to non-severe patients (96.0% vs. 5.4%; $P \le 0.001$) and survivors (80.0% vs. 22.6%; $P \le 0.001$). In hospital mortality rates were significantly higher with

severe compared to non-severe disease (32.0% vs. 6.9%; $P \le 0.001$). The median (IQR) duration of hospital stay of all studied patients was 14 days (3-29), with significant longer durations in severe patients (22 days (10-29) vs. 10 days (3-22); $P \le 0.001$) and non-survivors (22 days (3-29) vs. 12 days (3-29); P=0.001) compared to their corresponding groups.

115 Laboratory findings:

116 Those with severe disease and non-survivors exhibited significantly higher (P ≤ 0.05) coagulation function (D-dimer), inflammation (PCT, ESR, CRP, and ferritin), liver dysfunction 117 (AST and ALT), and tissue damage (LDH) compared to their corresponding groups. On the other 118 119 hand, their CBCs showed significantly lower absolute lymphocyte counts (P ≤ 0.05) with significantly higher absolute neutrophil counts ($P \le 0.05$). There were no significant differences 120 (P > 0.05) in hemoglobin level, total leukocyte and platelet counts between the studied 121 122 categories. Table 3 shows the biochemical and hematological characteristics of the included patients. 123

124 Indicators of COVID-19 severity and in-hospital mortality:

125 In table 4, multivariate logistic regression analysis was used to identify independent prognosis indicators associated with COVID-19 severity and in-hospital mortality. Predictors of COVID-126 127 19 severity in the studied patients were presence of COPD (OR: 3.294; 95% CI: 1.199-9.053; P= 0.021) and diabetes mellitus (OR: 2.951; 95% CI:1.070-8.137; P= 0.037) as co-morbidities, 128 129 abnormal high values of ferritin $\geq 350 \text{ ng/mL}$ (OR: 11.08; 95% CI: 2.796-41.551; P= 0.001), 130 AST \geq 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991; P= 0.021) and CT-SS \geq 17 (OR: 1.205; 95% CI: 1.089-1.334; $P \le 0.001$), as well as low absolute lymphocyte count $< 1 \times 103/\mu L$ (OR: 4.002; 131 95% CI: 1.537-10.421; P = 0.005). The presence of dyspnea as a presenting symptom (OR: 132

4.006; 95% CI: 1.045-15.359; P= 0.043), CT-SS \geq 17 (OR: 1.271; 95% CI: 1.091-1.482; P= 0.002) and AST \geq 40 IU/L (OR: 2.89; 95% CI: 1.091-7.661; P= 0.033) were also found to be independent predictors of COVID-19 in-hospital mortality.

136 **DISCUSSION:**

In the current study, comprehensive data analysis on the demographic, clinical, laboratory and
radiological characteristics and outcomes of 180 hospitalized adult Egyptian COVID-19 patients
were presented. The non-severe cases of COVID-19 (72.2%), as well as the survivors (86.1%),
were by far the most prevalent in this study.

141 This study revealed that the severity and mortality of COVID-19 were significantly predominant in the older age groups. This could be explained by the age-dependent decline in cell-mediated 142 and humoral immune functions, resulting from low-grade chronic inflammation [12], as well as 143 144 the increased risk of multi-organ failure in elderly individuals due to their lower ability to correct for hypoxia [13]. In agreement with our findings, several studies reported that elderly patients 145 146 with COVID-19 are more likely to progress to severe disease with worse outcomes, compared to young and middle-aged patients [14-16]. In contrast, Wang and colleagues couldn't link COVID-147 19 severity or mortality to a certain age group [17]. 148

According to several studies, COVID-19 has infected more males than females, [18,19]. Female gender may be a protective factor, as evidenced by the fact that women have fewer harmful habits than men, particularly smoking [20]. Females may also have stronger innate and adaptive immune responses than males, making them more resistant to infections [21]. In terms of COVID-19 severity and morality, our research found no significant differences between male and female patients. Wang et al. and Fois et al., like us, discovered no gender differences in disease severity or mortality [12,22].

156 Diabetes mellitus, hypertension, and COPD were the most common chronic disorders among 157 COVID-19 participants in our study. These co-morbidities were found to be strongly linked to disease progression. In addition, the odds of COVID-19 severity were 3.294 and 2.951 folds 158 159 greater in COPD and diabetic patients, respectively. These findings were in line with a metaanalysis research that found diabetes mellitus and hypertension to be of the most common 160 underlying disorders among COVID-19 patients who were hospitalized [23]. Consistent with our 161 findings, Marhl et al. found a greater risk of COVID-19 in diabetic individuals due to the related 162 dysregulation of angiotensin-converting enzyme-2 (ACE-2), liver dysfunction, and chronic 163 164 inflammation [24]. In addition, the elevated risk of COVID-19 infection in patients with pre-165 existing cardiovascular illness may be due to a decrease in pro-inflammatory cytokines, which leads to weakened immune function [25]. In previous studies on MERS-CoV-2, it was 166 167 discovered that the virus's particular receptor, dipeptidyl peptidase-4, was expressed at a higher level in smokers and COPD patients [26]. Emami et al. suggested that COPD could be an 168 169 underlying factor that makes patients more prone to COVID-19 development [23], which is 170 similar to our findings. Zhang et al., on the other hand, were unable to relate COVID-19 to COPD [27]. 171

The most common symptoms found at admission of our COVID-19 patients were; fatigue (90.6%), myalgia (75%), arthralgia (74%), fever (69.4%), dyspnea (69.4%), and cough (68.9%). In accordance to our results, Ghweli and co-workers found that malaise, fever, dry cough, and dyspnea, were the most common manifestations of COVID-19 [14]. Dyspnea was found to be a significant prominent feature among the non-survivors in this study. Furthermore, the risk of disease mortality was 4.006 times higher in patients who presented with dyspnea than in those who did not. Similarly, Zheng et al. reported a significant positive association of dyspnea with

179 COVID-19 progression to death [28]. Also, a meta-analysis study reported similar findings and 180 recommended dyspnea rather than fever as an indicator of poor outcome in COVID-19 patients 181 [29].

Individuals with COVID-19 may have coagulation abnormalities, promoting a hypercoagulable state and resulting in an increased rate of thrombotic and thromboembolic events [30]. Using whole blood thromboelastography, Panigada et al. identified hypercoagulability features in COVID-19 patients, such as a decrease in time to fibrin formation, a decrease in time to clot formation, and an increase in clot strength [31]. In the context of these findings, a significant proportion of severe patients in our study were presented with thrombotic manifestations at admission to the hospital.

Severe patients tend to get priority hospitalization, with an increased need for oxygen supplementation, intensive care, and even mechanical ventilation [18]. Similarly, in our study, the length of hospital stay and the necessity for ICU admission were both considerably higher in severe patients and non-survivors.

Regarding complete blood count in COVID-19, peripheral blood leukocyte and lymphocyte 193 counts are found to be normal or slightly reduced during the early phase of the disease, when 194 195 non-specific symptoms are present. Approximately 1 to 2 weeks from the onset of the initial 196 symptoms, when there is a surge in the clinical manifestations of the disease coinciding with a 197 pronounced systemic increase of inflammatory mediators and cytokines, significant lymphopenia 198 becomes evident [32]. Several factors may contribute to COVID-19-associated lymphopenia: the 199 virus may directly infect lymphocytes, resulting in their lysis; the markedly increased levels of 200 interleukins may promote lymphocyte apoptosis; the cytokine storm may be associated with 201 lymphoid organ atrophy; and the metabolic acidosis present in severe COVID-19 patients may

202 suppress the proliferation of lymphocytes [32]. On the other hand, neutrophils are triggered by 203 virus-related inflammatory factors produced by lymphocytes and endothelial cells, releasing 204 large amounts of reactive oxygen species, neutrophil extracellular traps, and other cytotoxic 205 mediators, which may dampen the virus [33]. Also, platelets may have an important role in the regulation of virus-mediated inflammatory process [34]. The platelet count of most mild to 206 moderate COVID19 patients may be normal or elevated but it may be reduced in critically ill 207 208 patients. In individuals with severe COVID19, thrombocytopenia may be caused by a decrease in 209 platelet production, an increase in platelet breakdown, or a decrease in circulating platelets [35].

210 In the current study, the hematological indices of the included COVID-19 patients revealed 211 significantly lower median absolute lymphocyte counts and higher median absolute neutrophil counts; yet without neutrophilia, among severe patients and non-survivors. Also, lymphopenia < 212 1 x $10^{3}/\mu$ L was an independent predictor of disease severity (OR: 4.002). However, total 213 214 leukocytic count, hemoglobin level, and platelet counts showed no significant differences as the 215 disease progressed. In accordance to our results, lymphopenia has been recognized in many 216 studies as an effective and reliable indicator of severity and mortality in COVID-19 patients [14,18,36]. Also, many studies reported that non-survivors presented with significantly higher 217 neutrophil counts [4,36,37]. Moreover, Shang et al. found that hemoglobin levels were not 218 219 influenced by the severity of the disease [38]. As opposed to our findings, Li et al. have found significant leucopenia and thrombocytopenia in the severe patients [18]. In addition, Sulejmani et 220 221 al. reported significant leukocytosis in severe COVID-19 patients, which could be related to the 222 hyper-inflammatory state [39].

It has been reported that viral infection could induce an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction. Additionally, viral infection induces

225 acute phase reactant production [40]. CRP is an inflammatory marker that plays an important 226 role in host resistance to invading pathogens. Higher CRP values have been linked to several unfavorable aspects of COVID-19 including, cardiac injury, respiratory distress, and death. The 227 detection of CRP levels was reported to be of great value in assessing the severity of COVID-19 228 229 patients [4]. Binding and storage of iron, which are functions of ferritin, are also associated with 230 immune and inflammatory response to viral infection [41]. Procalcitonin (PCT) has been recently suggested as a valuable inflammatory prognostic biomarker in identifying COVID-19 231 232 patients at high risk for clinical deterioration [42]. Our findings revealed significantly higher 233 inflammatory and tissue damage markers (CRP, ESR, ferritin, PCT, and LDH) among severe 234 COVID-19 patients and those who died from the disease. Also, ferritin \geq 350 ng/mL was an 235 independent predictor of COVID-19 severity with an odds ratio of 11.08. These findings were in 236 agreement with several other studies [4,18,41,42].

Coagulation disorders are relatively frequently encountered among severe COVID-19 patients. The D-dimer dynamics can reflect disease severity and elevated D-dimer level is associated with adverse patients' outcomes [14,30]. In accordance, D-dimer levels in our studied patients increased significantly as the disease worsened.

One of the mechanisms by which COVID-19 can invade the human body is by binding to human ACE-2 receptor with subsequent enhancement of ACE-2 expression in hepatocytes [43]. Chen et al. discovered a slight increase in ALT and AST serum values in 43.4% of COVID-19 cases from Wuhan, which was the first report of hepatic dysfunction in SARS-CoV-2 infection [36]. A link between aberrant liver biochemistry and COVID-19 severity has recently been discovered [18]. In a study in Shanghai, severe to critical cases exhibited significantly higher serum ALT and AST levels than those who had mild to moderate COVID-19 [44]. In line with these

findings, the present study revealed significantly higher serum values of both ALT and AST among severely infected COVID-19 patients and those who died from the disease. In addition, AST \geq 40 IU/L was an independent predictor of COVID-19 severity and mortality with an odds ratio of 3.076 and 2.890, respectively.

The use of CT imaging for the diagnosis and grading of viral pneumonia, allows patients with 252 suspected SARS-CoV-2 infection to be isolated and treated in time for recovery, thus optimizing 253 254 patient management [45]. Ground-glass opacities, consolidations and Broncho vascular 255 thickening are characteristic chest CT findings in COVID-19 pneumonia. Atypical chest CT 256 features also include masses, nodules, cavitation, lymphadenopathy, and pleural effusion [46]. The CT-scoring system (CT-SS), which has a high predictive value for the dynamic changes in 257 chest CT exams in different severities of COVID-19 pneumonia [46], can be used to assess the 258 259 extent of lung involvement. Both lungs were divided into 12 zones in total in the scoring 260 methodology of Zhou et al; the degree of involvement in each lung zone was scored from 0 to 4, 261 with a maximum achievable score of 48 [47]. Yang and coworkers developed another scoring 262 system in which both lungs were divided into 20 zones and examined on chest CT using a methodology that assigned scores of 0, 1, and 2; hence, the individual's total score may vary 263 from 0 to 40 points [48]. In this current study, the lung lobar involvement scoring system (0-25)264 was used as it was practical and time-effective [10,11,46], and showed significantly higher 265 scores in the severe and non-survivor patients. Moreover, the odds of disease severity and 266 mortality were 1.205 and 1.271 folds higher with CT-SS of \geq 17, respectively. In accordance to 267 268 our findings, in a study by Hafez et al., CT-SS 18/24 was considered the cutoff value among the 269 mild and severe cases [46]. Also, Francone et al. have stated that CT-SS of \geq 18 is highly 270 predictive of COVID-19 mortality [10].

271 This study has some limitations that should be considered. First, it is a retrospective study that 272 was performed in a limited hospital setting and included a relatively small sample size with 273 disproportion in the different study groups. A large multi-center prospective observational study 274 would be better to authenticate our findings. Another limitation is that all data included in this study were from the official records of the hospital; meanwhile, some patients have not been 275 hospitalized for treatment because of the lack of awareness of disease severity, as well as the 276 277 shortage of heath care facilities. A larger study that includes out-patients isolated at home in 278 addition to hospitalized in-patients, would offer a more representative study population.

279 **CONCLUSIONS:**

According to this study, COVID-19 infection was more aggressive in the elderly, diabetic, hypertensive, and COPD patients, as well as in those with low lymphocyte counts, high neutrophil counts, and high CRP, ESR, PCT, LDH, D-dimer, ferritin, AST, and ALT levels at the time of their admission to hospital. Hence, pretreatment clinical and laboratory data from COVID-19 patients at hospital admission may aid in identifying early risk factors for disease progression, as well as determining the most effective management plan.

286 Abbreviations:

ACE-2: Angiotensin-converting enzyme-2; COPD: Chronic obstructive pulmonary disease; COVID-19: Coronavirus disease 2019; CT-SS: CT-scoring system; RT- PCR: Reverse transcription-polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome corona virus 2; WHO: World Health Organization.

291 **Manuscript word count:** 3290 words

- 292 Abstract word count: 285 words
- 293 **Tables:** 4

- 294 **Figures:** 0
- **Data availability statement:** Data will be available upon request.
- 296 Acknowledgement: None.
- 297 **Conflicts of interest disclosure:** None.
- 298 **Funding sources:** None
- 299 **Consent for publication:** Not applicable.

300 Authors contribution:

- 301 Sara I. Taha: conceptualization, methodology, writing- reviewing and editing; Sara F. Samaan
- 302 and Aalaa K. Shata: data curation, investigation; Shereen A. Baioumy; project visualization,
- 303 resources, software, validation; *Shaimaa A. Abdalgeleel:* formal analysis, supervision; *Mariam*
- 304 *K. Youssef:* writing-original draft preparation, project administration.

305 **REFERENCES:**

- [1] Balkhair AA. COVID-19 pandemic: a new chapter in the history of infectious diseases.
 Oman Med J; 202035(2): e123. DOI: 10.5001/omj.2020.41. PMID: 32328297; PMCID:
 PMC7171815.
- 309 [2] Egyptian Ministry of Health. https://www.care.gov.eg/EgyptCare/Index.aspx. Accessed
 310 5 June, 2021.
- [3] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in
 Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Mar
 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. PMID:31995857; PMCID:
 PMC7121484.

315	[4] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
316	with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15;395(10223):497-506.
317	doi: 10.1016/S0140-6736(20)30183-5. PMID: 31986264; PMCID: PMC7159299
318	[5] Heo, J., Han, D., Kim, HJ, Kim D, Lee YK, Lim D, et al. Prediction of patients requiring
319	intensive care for COVID-19: development and validation of an integer-based score
320	using data from Centers for Disease Control and Prevention of South Korea. J Intensive
321	Care. 2021 Jan 29;9(1):16. doi: 10.1186/s40560-021-00527-x. PMID: 33514443 PMCID:
322	PMC7844778.
323	[6] Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an
324	indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J
325	Transl Med. 2020 Oct 29;18(1):406. doi: 10.1186/s12967-020-02571-x. PMID:
326	33121497; PMCID: PMC7594951.
327	[7] World Health Organization. DRAFT landscape and tracker of COVID-19 candidate
328	vaccines. who.int. Update May 28, 2021. Accessed May 30,
329	2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-
330	vaccines.
331	[8] WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human
332	cases, interim guidance. 2020. p. 1-7. Available from: https://www.who.int/publications-
333	detail/laboratory-testing-for-2019-novel-coronavirus-in-sus-pected-human-cases-
334	<u>20200117</u> .
335	[9] Abdelfattah E, Ahmed S, El-Zahapy H, EL Said A, Salem S, Tharwat A, et al., Hospital
336	response to COVID-19 a consensus: Report on Ain Shams University Hospital Strategy.

337	[published online ahead of print, June 12, 2020]. ScienceOpen. doi:
338	https://doi.org/10.14293/S2199-1006.1.SORPPD4QZX.v1
339	[10] Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L et al. Chest CT score in
340	COVID-19 patients: correlation with disease severity and short-term prognosis. Eur
341	Radiol. 2020; 4:1 – 10
342	[11] Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes at Chest
343	CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020;
344	295:715 -721.
345	[12] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
346	Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
347	China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum
348	in: JAMA. 2021 Mar 16;325(11):1113. PMID: 32031570; PMCID: PMC7042881.
349	[13] Zou Z, Yang Y, Chen J, Xin S, Zhang W, Zhou X, et al. Prognostic factors for severe
350	acute respiratory syndrome: a clinical analysis of 165 cases. Clin Infect Dis. 2004 Feb
351	15;38(4):483-9. doi: 10.1086/380973. Epub 2004 Jan 28. PMID: 14765339; PMCID:
352	PMC7107942.
353	[14] Ghweil AA, Hassan MH, Khodeary A, Mohamed AO, Mohammed HM, Abdelazez AA,
354	et al. Characteristics, Outcomes and Indicators of Severity for COVID-19 Among Sample
355	of ESNA Quarantine Hospital's Patients, Egypt: A Retrospective Study. Infect Drug

Resist. 2020 Jul 17; 13:2375-2383. doi: 10.2147/IDR.S263489. PMID: 32765012;
PMCID: PMC7381791.

- 358 [15] Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A
- comparison with young and middle-aged patients. J Infect. 2020 Jun;80(6):e14-e18. doi:
- 360 10.1016/j.jinf.2020.03.005. Epub 2020 Mar 27. PMID: 32171866; PMCID: PMC7102640.
- **[16]** Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates. BMJ.
- 362 2020 Apr 1;369:m1327. doi: 10.1136/bmj.m1327. PMID: 32238354.
- [17] Wang C, Deng R, Gou L, Fu Z, Zhang X, Shao F, et al. Preliminary study to identify
 severe from moderate cases of COVID-19 using combined hematology parameters. Ann
 Transl Med. 2020 May;8(9):593. doi: 10.21037/atm-20-3391. PMID: 32566620; PMCID:
 PMC7290538.
- [18] Li X, Xu Z, Wang T, Xu X, Li H, Sun Q, et al. Clinical laboratory characteristics of 367 severe patients with coronavirus disease 2019 (COVID-19): A systematic review and 368 369 meta-analysis. Clin Epidemiol Glob Health. 2021 Jan-Mar;9:184-190. doi: 10.1016/j.cegh.2020.08.012. Epub 2020 Sep 15. PMID: 370 32954048; PMCID: 371 PMC7491425.
- [19] Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease
 Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel
 coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020
 Feb 10;41(2):145-151. Chinese. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. PMID:
 32064853.
- [20] Manavi KR, Alston-Mills BP, Thompson MP. History of tobacco, vitamin D and women.
- 378 Int J Vitam Nutr Res. 2020 Oct;90(5-6):389-394. doi: 10.1024/0300-9831/a000640. Epub
- 379 2020 Feb 24. PMID: 32091316.

380	[21] Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. Clin Rev
381	Allergy Immunol. 2019 Jun;56(3):308-321. doi: 10.1007/s12016-017-8648-x. PMID:
382	28963611.

- 383 [22] Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The Systemic
- Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients.
 Molecules. 2020 Dec 4;25(23):5725. doi: 10.3390/molecules25235725. PMID: 33291581;
- 386 PMCID: PMC7731255

401

- [23] Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in
 Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Arch
 Acad Emerg Med. 2020 Mar 24;8(1): e35. PMID: 32232218; PMCID: PMC7096724.
- [24] Marhl M, Grubelnik V, Magdič M, Markovič R. Diabetes and metabolic syndrome as
 risk factors for COVID-19. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):671-677. doi:
- 392 10.1016/j.dsx.2020.05.013. Epub 2020 May 8. PMID: 32438331; PMCID: PMC7205616.
- [25] Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat
- Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. PMID:
 32139904; PMCID: PMC7095524.
- [26] Seys LJM, Widagdo W, Verhamme FM, Kleinjan A, Janssens W, Joos GF, et al. DPP4,
 the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of
 Smokers and Chronic Obstructive Pulmonary Disease Patients. Clin Infect Dis. 2018 Jan
 6;66(1):45-53. doi: 10.1093/cid/cix741. PMID: 29020176; PMCID: PMC7108100.
- 400 [27] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics
- 402 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27. PMID: 32077115.

21

of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020

- [28] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal
 COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020
 Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23. PMID:
 32335169; PMCID: PMC7177098.
- [29] Shi L, Wang Y, Wang Y, Duan G, Yang H. Dyspnea rather than fever is a risk factor for
 predicting mortality in patients with COVID-19. J Infect. 2020 Oct;81(4):647-679. doi:
 10.1016/j.jinf.2020.05.013. Epub 2020 May 15. PMID: 32417316; PMCID:
 PMC7228739.
- [30] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. Global 411 COVID-19 Thrombosis Collaborative Group, endorsed by the ISTH, NATF, ESVM, and 412 the IUA, supported by the ESC Working Group on Pulmonary Circulation and Right 413 414 Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: 415 Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-416 Review. Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: Art J Am 417 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. PMID: 32311448; PMCID: PMC7164881. 418
- [31] Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al.
 Hypercoagulability of COVID-19 patients in intensive care unit: A report of
 thromboelastography findings and other parameters of hemostasis. J Thromb Haemost.
 2020 Jul;18(7):1738-1742. doi: 10.1111/jth.14850. Epub 2020 Jun 24. PMID: 32302438.
- 423 [32] Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts
- 424 disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target

- 425 Ther. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4. PMID: 32296069; PMCID:
 426 PMC7100419.
- 427 **[33]** Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immune-Inflammatory Parameters

in COVID-19 Cases: A Systematic Review and Meta-Analysis. Front Med (Lausanne).

428

- 429 2020 Jun 9; 7:301. doi: 10.3389/fmed.2020.00301. PMID: 32582743; PMCID:
 430 PMC7295898.
- [34] Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19
 patients in the emergency room. Biomark Med. 2020 Sep;14(13):1207-1215. doi:
 10.2217/bmm-2020-0317. Epub 2020 Jul 21. PMID: 32692248; PMCID: PMC7372996.
- [35] Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann
 Hematol. 2020 Jun;99(6):1205-1208. doi: 10.1007/s00277-020-04019-0. Epub 2020 Apr
 15. PMID: 32296910; PMCID: PMC7156897.
- [36] Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, et al. Laboratory
 predictors of death from coronavirus disease 2019 (COVID-19) in the area of
 Valcamonica, Italy. Clin Chem Lab Med. 2020 Jun 25;58(7):1100-1105. doi:
 10.1515/cclm-2020-0459. PMID: 32573995.
- [37] Eastin C, Eastin T. Clinical Characteristics of Coronavirus Disease 2019 in China: Guan
 W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI:
 10.1056/NEJMoa2002032. J Emerg Med. 2020 Apr;58(4):711–2. doi:
 10.1016/j.jemermed.2020.04.004. Epub 2020 Jun 3. PMCID: PMC7266766.
- [38] Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in
 predicting the severity of COVID-19. J Med Virol. 2020 Oct;92(10):2188-2192. doi:
 10.1002/jmv.26031. Epub 2020 Jun 2. PMID: 32436996; PMCID: PMC7280691.

- [39] Sulejmani A, Galimberti E, Giacobone C, Milano A, Scopetta E, Intra J, et al. Baseline
 characteristics of COVID-19 Italian patients admitted to Desio Hospital, Lombardy: a
 retrospective study. Scand J Clin Lab Invest. 2021 Feb;81(1):18-23. doi:
- 451 10.1080/00365513.2020.1846211. Epub 2021 Jan 6. PMID: 33403882.
- [40] Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and
 Treatment of Coronavirus (COVID-19). 2021 Apr 20. In: StatPearls [Internet]. Treasure
- 454 Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32150360.
- [41] Lalueza A, Ayuso B, Arrieta E, Trujillo H, Folgueira D, Cueto C, et al; INFLUDOC
 group. Elevation of serum ferritin levels for predicting a poor outcome in hospitalized
 patients with influenza infection. Clin Microbiol Infect. 2020 Nov;26(11): 1557.e9-
- 458 1557.e15. doi: 10.1016/j.cmi.2020.02.018. Epub 2020 Feb 28. PMID: 32120038.
- [42] Schuetz P.The Role of Procalcitonin for Risk Assessment and Treatment of COVID-19
 Patients. HealthManagement. 2020;20(5):380-82.
- [43] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
 descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S01406736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.
- [44] Lu H, Ai J, Shen Y, Li Y, Li, T, Zhouet X ,et al. A descriptive study of the impact of
 diseases control and prevention on the epidemics dynamics and clinical features of SARSCoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention.
 medRxiv 2020.02.19.20025031; doi: https://doi.org/10.1101/2020.02.19.20025031;
 Gonline ahead of print].

470 [45] Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in D	Jiagnosis a	nd
--	-------------	----

- 471 Management. AJR Am J Roentgenol. 2020 Jun;214(6):1280-1286. doi:
 472 10.2214/AJR.20.22954. Epub 2020 Mar 4. PMID: 32130038.
- 473 [46] Hafez MAF. The mean severity score and its correlation with common computed
- tomography chest manifestations in Egyptian patients with COVID-2019 pneumonia.
- 475 Egypt J Radiol Nucl Med. 2020;51(1):254. doi: 10.1186/s43055-020-00368-y. Epub 2020
- 476 Dec 8. PMCID: PMC7721816.
- 477 [47] Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus Disease 2019 (COVID-19)
- 478 Pneumonia in 62 Patients in Wuhan, China. AJR Am J Roentgenol. 2020
- 479 Jun;214(6):1287-1294. doi: 10.2214/AJR.20.22975. Epub 2020 Mar 5. PMID: 32134681.
- [48] Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT Severity Score: An
 Imaging Tool for Assessing Severe COVID-19. Radiol Cardiothorac Imaging. 2020 Mar
 30;2(2): e200047. doi: 10.1148/ryct.2020200047. PMID: 33778560; PMCID:
- 483 PMC7233443.

484 **Table 1:** Sociodemographic characteristics and co-morbidities of all studied patients and

485 according to COVID-19 severity and mortality.

		TOTAL	SEVERITY			MORTALITY			
		N=180	Non-severe N=130	Severe N=50	p- value	Survivors N= 155	Non- survivors N= 25	p- value	
Age (years)	Median (IQR)	48.0 (15-94)	43 (15-94)	60 (22-91)	0.004	45.0 (15-94)	57.0 (27-80)	0.005	
Sex n., %	Male	63 (35.0%)	41 (31.5%)	22 (44.0%)	0.116	53 (34.2%)	10 (40.0%)	0.572	
Sex II., 70	Female	117 (65.0%)	89 (68.5%)	28 (56.0%)	0.110	102 (65.8%)	15 (60.0%)		
	Diabetes	84 (46.7%)	49 (37.7%)	35 (70.0%)	≤0.001	67 (43.2%)	17 (68.0%)	0.021	
	HTN	65 (36.1%)	36 (27.7%)	29 (58.0%)	≤0.001	49 (31.6%)	16 (64.0%)	0.002	
	IHD	25 (13.9%)	14 (10.8%)	11 (22.0%)	0.051	18 (11.6%)	7 (28.0%)	0.028	
Co-morbidities n., %	Stroke	9 (5.0%)	3 (2.3%)	6 (12.0%)	0.008	4 (2.6%)	5 (20.0%)	0.003	
	CKD	8(4.4%)	1 (0.8%)	7 (14.0%)	<u>≤</u> 0.001	6 (3.9%)	2 (8.0%)	0.353	
	CLD	36 (20.0%)	20 (15.4%)	16 (32.0%)	0.013	31 (20.0%)	5 (20.0%)	1.000	
	COPD	60 (33.3%)	35 (26.9%)	25 (50.0%)	0.003	52 (33.5%)	8 (32.0%)	0.879	

486 CKD: chronic kidney disease; CLD, chronic liver disease; COPD: chronic obstructive

487 pulmonary disease; HTN, hypertension; IHD: ischemic heart disease. Significance (P-value) was

488 *set at* ≤0.05.

489 **Table 2:** Clinical characteristics and outcomes of all studied patients and according to COVID-

490 19 severity and mortality.

		TOTAL	S	EVERITY		MORTALITY		
		TOTAL	Non-severe	Severe	p-value	Survivors	Non- survivors	p-value
		N=180	N=130	N=50		N= 155	N= 25	
	Fatigue	163 (90.6%)	119 (91.5%)	44 (88.0%)	0.467	142 (91.6%)	21 (84.0%)	0.227
	Fever	125 (69.4%)	89 (68.5%)	36 (72.0%)	0.644	109 (70.3%)	16 (64.0%)	0.524
	Dyspnea	125 (69.4%)	88 (67.7%)	37 (74.0%)	0.411	103 (66.5%)	22 (88.0%)	0.030
	Arthralgia	133 (73.9%)	93 (71.5%)	40 (80.0%)	0.247	115 (74.2%)	18 (72.0%)	0.817
	Myalgia	135 (75.0%)	98 (75.4%)	37 (74.0%)	0.848	115 (74.2%)	20 (80.0%)	0.534
	Cough	124 (68.9%)	86 (66.2%)	38 (76.0%)	0.201	104 (67.1%)	20 (80.0%)	0.196
Symptoms	Anosmia	37 (20.6%)	28 (21.5%)	9 (18.0%)	0.599	34 (21.9%)	3 (12.0%)	0.254
n., (%)	Rhinitis	18 (10.0%)	16 (12.3%)	2 (4.0%)	0.096	17 (11.0%)	1 (4.0%)	0.281
(/0)	Headache	65 (36.1%)	46 (35.4%)	19 (38.0%)	0.744	55 (35.5%)	10 (40.0%)	0.663
	Chest tightness	71 (39.4%)	50 (38.5%)	21 (42.0%)	0.664	57 (36.8%)	14 (56.0%)	0.068
	Sore throat	26 (14.4%)	19 (14.6%)	7 (14.0%)	0.916	23 (14.8%)	3 (12.0%)	0.708
	Nausea	22 (12.2%)	18 (13.8%)	4 (8.0%)	0.283	20 (12.9%)	2 (8.0%)	0.487
	Diarrhea	20 (11.1%)	16 (12.3%)	4 (8.0%)	0.410	19 (12.3%)	1 (4.0%)	0.223
	Loss of taste	12 (6.7%)	11 (8.5%)	1 (20.0%)	0.120	11 (7.1%)	1 (4.0%)	0.565
	Thrombosis	48 (26.7%)	29 (22.3%)	19 (38.0%)	0.030	39 (25.2%)	9 (36.0%)	0.255
CT-SS			<u>≤0.001</u>	7 (0-23)	20 (0-24)	≤0.001		
ICU admission	n., (%)	55 (30.6%)	7 (5.4%)	48 (96.0%)	≤0.001	35 (22.6%)	20 (80.0%)	≤0.001
Hospital stay (days)	Median (IQR)	14 (3-29)	10 (3-22)	22 (10-29)	≤0.001	12 (3-29)	22 (3-29)	0.001
In-hospital mortality	Discharged alive	155 (86.1%)	121 (93.1%)	34 (68.0%)	≤0.001			
n., (%)	Died	25 (13.9%)	9 (6.9%)	16 (32.0%)	≤0.001			

CT-SS: CT-scoring system. Significance (P-value) was set at ≤ 0.05 .

492 **Table 3:** Baseline laboratory findings of all studied patients and according to COVID-19

493 severity and mortality.

	TOTAL	S	EVERITY	MORT			
		Non-severe	Severe	p-value	Survivors	Non-survivors	p-
	n=180	n=130	n=50	p-value	n= 155	n= 25	value
TLC (×10 ³ /μl)	7.6 (0.1-79.0)	7.5 (1.2-79.0)	7.9 (0.1-24.0)	0.856	7.6 (0.1-79.0)	7.6 (1.2-21.6)	0.849
NL (×10 ³ /μl)	2.5 (0.9-5.8)	1.9 (0.9-4.2)	2.9 (0.9-5.8)	≤0.001	2.1 (0.9-4.2)	2.6 (0.9-5.8)	0.001
LYMPH (×10 ³ /µl)	1.2 (0.0-6.0)	1.5 (0.1-6.6)	0.9 (.0-3.6)	≤0.001	1.3 (0.0-6.6)	1.1 (0.1-2.4)	0.005
HB (gm/dl)	11.4 (2.9-16.7)	11.5(5.0-16.7)	10.5 (2.9-15.0)	0.280	11.2 (2.9-16.7)	12.4 (6.6-15.2)	0.104
PLT (×10 ³ /µl)	251.5 (6-716)	254.0 (6-716)	240.0 (11-650)	0.627	256.0 (6-716)	208.0 (6-485)	0.124
Ferritin (ng/mL)	371.5 (16-4947)	215.5 (16-2273)	860.5 (130-4947)	≤0.001	342.0(16-4947)	878 (130-2577)	≤0.001
PCT (ng/mL)	0.9 (0-5.9)	0.8 (0.0-5.1)	2.8 (0.4-5.9)	≤0.001	0.9 (.0-5.9)	2.5 (0.6-5.9)	≤0.001
ESR (mm/h)	70.0 (12-210)	57.0 (12-140)	110.0 (49-210)	≤0.001	65.0 (12-187)	110 (30-210)	≤0.001
CRP (mg/L)	48.0 (6.0-378.0)	29.5 (6.0-372.0)	102.5 (11-378.0)	≤0.001	45.0 (6.0-378)	91 (10-304)	0.007
D-dimer (mg/L)	1.1 (0.1-12.5)	0.8 (0.1-12.5)	2.5 (0.7-12.2)	≤0.001	0.9 (0.1-9.5)	3.4 (0.6-12.5)	≤0.001
LDH (IU/L)	222.0 (18-1889)	189.0 (18-1889)	392.0 (46-1121)	≤0.001	207 (18-1889)	388 (123 -1091)	0.002
AST (IU/L)	26.0 (2-2044)	25.0 (11-2044)	45.0 (2-898)	0.018	25 (2-2044)	45 (12-898)	0.002
ALT (IU/L)	30.0 (10-1344)	25.0 (10-1344)	45.0 (10-511)	≤0.001	27 (10-1344)	45 (18-511)	0.001

494 ALT: Alanine amino transferase; AST: Aspartate aminotransferase; CRP: C-reactive protein;

495 ESR: Erythrocyte sedimentation rate; HB: Hemoglobin; LDH: Lactate dehydrogenase; Lymph:

496 Lymphocytes; PCT: Procalcitonin; PLT: Platelets; NL: Neutrophils; TLC: Total leukocytic

497 *count. Data presented as median (IQR). Significance (P-value) was set at* ≤ 0.05 .

498 **Table 4:** Multivariate logistic regression analysis of risk factors associated with COVID-19

Variables	SEVERITY							
variables	В	S.E.	P-value	Odds ratio	95% CI			
Diabetes	1.082	0.518	0.037	2.951	1.070-8.137			
СОРД	1.192	0.516	0.021	3.294	1.199-9.053			
CT-SS (≥ 17)	1.416	0.673	≤ 0.001	1.205	1.089-1.334			
Ferritin (≥ 350 ng/mL)	2.405	0.702	0.001	11.08	2.796-41.551			
AST (≥ 40 IU/L)	1.124	0.487	0.021	3.07	1.842-7.991			
Lymphocytes (< 1×10 ³ /µL)	1.387	0.448	0.005	4.002	1.537-10.421			
	MORTALITY							
Dyspnea	1.388	0.686	0.043	4.006	1.045-15.359			
CT-SS (≥ 17)	2.023	0.792	0.002	1.271	1.091-1.482			
AST (≥ 40 IU/L)	1.061	0.497	0.033	2.89	1.091-7.661			

499 severity and in-hospital mortality.

500 AST: Aspartate aminotransferase; COPD: Chronic obstructive pulmonary disease; CT-SS: CT-

501 scoring system. Significance (*P*-value) was set at ≤ 0.05 .